Silodosin

• Description :

  Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].

• Product Name Alternative :

  KAD 3213; KMD 3213

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H373

• Target :

  Adrenergic Receptor; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Cancer; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/Silodosin.html

• Purity :

  99.82

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C(N)C1=CC(C[C@@H](C)NCCOC2=CC=CC=C2OCC(F)(F)F)=CC3=C1N(CC3)CCCO

• Molecular Formula :

  C25H32F3N3O4

• Molecular Weight :

  495.53

• Precautions :

  H302, H373

• References & Citations :

  [1]Maxime Rossi , Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297.|[2]Villa L, et al. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169 (1) :230-8.|[3]Osman NI, et al.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13 (14) :2085-96.|[4]Kawahara T, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5 (10) :2959-68. eCollection 2015.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [160970-54-7]